Today: 2 July 2026
Texas Instruments stock jumps 9% after outlook flags AI data-center demand
28 January 2026
2 mins read

Texas Instruments stock jumps 9% after outlook flags AI data-center demand

New York, January 28, 2026, 12:38 p.m. EST — Regular session

• Texas Instruments jumped in midday trading following a bullish first-quarter forecast
• The firm highlighted growing demand driven by AI data-center expansions and stronger industrial output
• Investors are cautious, waiting to see if the rally sticks as clients manage chip stockpiles

Texas Instruments shares surged 9.1% to $214.62 midday Wednesday after the chipmaker raised its first-quarter guidance above Wall Street expectations. The company forecast revenue between $4.32 billion and $4.68 billion, with earnings per share ranging from $1.22 to $1.48. CEO Haviv Ilan highlighted a 70% jump in data-center revenue during the December quarter, which now accounts for 9% of projected 2025 sales, while industrial demand climbed by the “high tens.” Stifel analyst Tore Svanberg described the inventory correction as “essentially complete.” Reuters

These figures are crucial since Texas Instruments occupies a key spot in the supply chain. Its analog and embedded chips appear in factory equipment, automobiles, and the steady, unflashy electronics that usually track the real economy.

Investors have been watching for signs that the analog-chip “inventory correction”—where customers run down stockpiles instead of placing new orders—is easing. The latest development: TI is treating data centers as a full business segment, not just a side note. That shift ties the company more directly to the AI spending cycle than many bulls anticipated.

TI reported $4.42 billion in revenue for the fourth quarter, with net income hitting $1.16 billion and earnings per share coming in at $1.27. The company noted that EPS was dragged down by 6 cents, a hit not included in its initial guidance. Ilan pointed out that revenue dropped 7% from the previous quarter but was up 10% compared to the same period last year. Over the past year, TI shelled out $4.6 billion on capital expenditures and returned $6.5 billion to shareholders.

B of A Securities analyst Vivek Arya acted fast, upgrading Texas Instruments from “underperform” to “neutral” and lifting his price target to $235 from $185, Benzinga reported. Benzinga

Unlike Nvidia, known for its high-end graphics processors powering AI training and inference, TI focuses on the quieter side — chips that handle power management and signal conversion to keep machines running smoothly. Analog Devices is a key competitor in this space.

The sector-wide AI rally is still driving the move, but it could reverse quickly. The Philadelphia SE Semiconductor index climbed 1.7%, though Reuters highlighted a global memory-chip shortage weighing on smartphones and PCs—a major market for TI. Morgan Stanley also flagged tariff and geopolitical risks, even as a TI supply crunch seems unlikely given low factory utilization. Louise Dudley, a portfolio manager at Federated Hermes, noted buyers are sensing “conditions are improving,” linking spending plans to overall sentiment. Reuters

Traders will be watching closely for follow-through: can TI’s data-center demand keep its momentum as the business ramps up? And will the industrial sector’s strength persist as orders flow into February? The next clear trigger comes Jan. 30—the record date for TI’s $1.42 quarterly dividend, payable Feb. 10, the company confirmed earlier this month.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Cramer Sees Moderna's Pipeline Opening Up Beyond Covid
    July 1, 2026, 7:50 PM EDT. CNBC's Jim Cramer said on Mad Money that Moderna now looks different than during the Covid rush, with a cancer pipeline and vaccines reaching outside infectious diseases. He sees many programs still years out but calls for buying pullbacks, pointing to Moderna's track to profits and new data from late-stage cancer trials-like the melanoma combo trial with Merck's Keytruda. Moderna shares have jumped almost 150% this year but still trade under pandemic highs. Cramer also mentions fresh regulatory wins, including FDA advisory backing for its flu shot and a European nod for its combined Covid-flu vaccine.
Oracle stock price today: ORCL edges higher as TikTok outage and new cloud wins grab focus
Previous Story

Oracle stock price today: ORCL edges higher as TikTok outage and new cloud wins grab focus

Intuit stock price dips as AI fears circle TurboTax, but RBC sticks with $850 target
Next Story

Intuit stock price dips as AI fears circle TurboTax, but RBC sticks with $850 target

Go toTop